Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

June 8, 2017

Quick Navi^TM-Mycoplasma Diagnostic Kit to Launch in Japan

Quick Navi^TM-Mycoplasma Diagnostic Kit to be launched as a new product of the Quick Navi Series
As with other products of the series, this simple-to-use diagnostic kit is rapid and displays the result clearly
Has excellent sensitivity and specificity to mycoplasma antigen.

Otsuka Pharmaceutical Co., Ltd. will commence sales in Japan from July 12, 2017, of the diagnostic test kit Quick Navi^TM-Mycoplasma. The kit, which can detect mycoplasma antigens quickly and with high sensitivity, is a new product in the Quick Navi Series of in vitro diagnostics.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Quick Navi^TM-Mycoplasma Diagnostic Kit to Launch in Japan

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan